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Abstract
Background: S100A12, a calcium-binding proinflammatory protein secreted by granulocytes, has been associated
with different diseases of inflammatory origin, including inflammatory bowel disease (IBD). In this study, the utility
of serum S100A12, in discriminating IBD from irritable bowel syndrome (IBS), was tested.
Methods: S100A12 serum levels were determined in 64 patients with ulcerative colitis (UC), 64 with Crohn’s
disease (CD) and 73 with IBS, by means of an enzyme-linked immunosorbent assay. S100A12 serum levels were
evaluated with respect to the levels of known inflammatory markers and patients’ characteristics.
Results: The median values of serum S100A12 levels were 68.2 ng/mL (range: 43.4-147.4) in UC, 70 ng/mL (41.4-169.8)
in CD and 43.4 ng/mL (34.4-74.4) in IBS patients. UC and CD patients had significantly higher serum S100A12 levels
compared to IBS patients (P = 0.001 for both comparisons). Moreover, a cut-off for serum S100A12 levels of 54.4 ng/mL
could predict both UC and CD with a 66.7% sensitivity and a 64.4% specificity. The area under curve was estimated at
0.67 with a 95% confidence interval of 0.60-0.75 (P < 0.001). Considering standard activity indices, higher serum
S100A12 levels in active compared to inactive IBD were observed, although the recorded difference did not reach
statistical significance. C-reactive protein (CRP) and serum amyloid A (SAA) levels, showed a statistically significant
positive correlation with S100A12 (r = 0.39, P = 0.001 and r = 0.23, P = 0.02 respectively).
Conclusions: Increased levels of circulating S100A12 are found in IBD, compared to IBS. When used to distinguish
IBD from IBS adult patients, serum S100A12 levels exhibit moderate performance. On the other hand, serum
S100A12 may serve as an inflammatory marker in IBD, since it is well correlated with CRP and SAA.
Background
Inflammatory bowel disease (IBD) remains a diagnostic
challenge for the clinician who faces a repertoire of
diverse and fluctuating symptoms and signs. It is mainly
due to a subtle or atypical presentation that in some
cases the discrimination of Crohn’sd i s e a s e( C D )o r
ulcerative colitis (UC), from other diseases of the ali-
mentary tract, especially from irritable bowel syndrome
(IBS), becomes rather problematic [1]. On the other
hand, although several markers are used for diagnostic
purposes [2] a simple, economic and reliable test, as an
alternative to more complex procedures for IBD diagno-
sis, is still under investigation. It is in this eager envir-
onment that S100A12 has emerged as a promising
marker for both diagnosis and disease activity in IBD
[3,4]. The S100A12, also known as calgranulin C, is a
member of the S100 protein family which, in humans,
consists of twenty five EF-hand (a helix-loop-a helix),
calcium-binding proteins, of which the vast majority is
in a homodimer, heterodimer ie S100A8/A9, or more
complex form [5]. S100A12, like S100A8/A9 (calprotec-
tin), is considered phagocyte-specific, exhibits proin-
flammatory properties and has already been linked to
many different diseases of inflammatory origin, includ-
ing IBD [3,4]. Several studies using the determination of
S100A12 in feces, revealed a significant association
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cially active disease [8], an association that could also
aid differential diagnosis by distinguishing IBD from IBS
[9]. A limited number of studies was also conducted to
examine the diagnostic potential of the S100A12 levels
in serum. To our knowledge, three studies have been
published so far, two carried out in pediatric [7,10] and
one in adult populations [8]. The present study, how-
ever, is the first testing the utility of serum S100A12
levels in discriminating IBD from IBS in adults, while at
the same time examining serum S100A12 titers with
respect to disease type (UC or CD) or activity, tradi-
tional markers of disease activity, patients’ characteris-
tics and treatment modalities.
Methods
Patients
A total of 201 patients followed at the Gastroenterology
Department of the University Hospital of Larissa, Greece
were recruited. Among these, 64 were UC and 64 CD
patients. Mean age ± SD was 51.2 ± 13.4 years for the
UC and 40.3 ± 15.6 years for the CD group. The control
group consisted of 73 outpatients, with mean age of 46.7
± 12.3 years, presenting with diarrhea ± abdominal pain,
who were diagnosed, after a full work-up (endoscopies,
histopathology, cultures etc), and classified as D-IBS or
M-IBS (51 and 22 individuals, respectively) according to
Rome III criteria [11]. The control group was both age
(P = 0.692) and sex (P = 0.126) matched with IBD
patients. The demographic and clinical characteristics of
UC and CD patients are presented in Table 1.
The diagnosis of IBD was established upon the co-
evaluation of findings originating from clinical and
endoscopic procedures, imaging studies, histopathology
and laboratory analyses. Disease activity in the IBD
group was documented using conventional indices:
Crohn’s Disease Activity Index (CDAI) [12] and the
Clinical Activity Index (CAI), for UC [13]. A CDAI
score greater than 150 and a CAI score exceeding 4, on
a 0-16 scale, were considered as active CD and active
UC, respectively. Disease location and behavior, in CD,
were determined using the Vienna classification [14]
whereas for disease extent, in UC, the Montreal classifi-
cation [15] was used.
Sample Collection and Preparation
Blood samples were collected in serum separator tubes
and were allowed to clot for 30 minutes. All samples
were then centrifuged and the obtained serum was
stored at -25°C, for later analysis. The pre-analytical
phase, including sampling and handling methods (sam-
pling tubes, storage conditions etc.) was identical in all
cases.
Laboratory Assays
S100A12 Assay
Serum S100A12 levels were determined by means of a
sandwich enzyme-linked immunosorbent assay (ELISA),
using a human diagnostic kit (INFLAMARK) produced
by CIS bio international (France). All samples were mea-
sured in duplicate (50 μl) within a standard range of
0-3000 ng/ml and with a total incubation time of 2 hours
and 10 minutes, in room temperature, using two mono-
clonal antibodies, one in the solid phase (coated micro
plates) and the other in the conjugate buffer. The detec-
tion limit of the assay was set at 20 ng/ml. If the differ-
ence between duplicate results of a sample was more
Table 1 Demographic and clinical characteristics for UC
and CD group
UC CD
N%N%
Total 64 64
Sex
Men 40 62.5 35 54.7
Women 24 37.5 29 45.3
Age, mean (SD) 51.2 (13.4) 40.3 (15.6)
Age at onset
≥40 yrs - 11 17.2
<40 yrs - 53 82.8
Current smoking
No 54 84.4 21 32.8
Yes 10 15.6 43 67.2
Disease duration, mean (SD), years 7.1 (0.3) 5.3 (0.3)
Disease extent (UC)
Proctitis 18 28.1 - -
Left-sided colitis 22 34.4 - -
Pancolitis 24 37.5 - -
Disease location (CD)
Ileitis - - 22 34.4
Colitis - - 11 17.2
Ileocolitis - - 31 48.4
Disease behavior
Stricturing - - 14 21.9
Penetrating - - 9 14.1
NS/NP - - 41 64
Extraintestinal manifestations
None 43 67.2 34 53.1
1 or more 21 32.8 30 46.9
Treatment
5-ASA 49 76.6 54 84.4
Corticosteroids 25 39.1 46 71.9
Immunosuppressants 14 21.9 21 32.8
Anti-TNF 3 4.7 16 25.0
Surgery 1 1.6 2 3.1
UC: ulcerative colitis, CD: Crohn’s disease, yrs: years, NS/NP: non stricturing
non penetrating.
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coefficient of variation was 4.1%.
CRP and SAA Assays
The determination of CRP and SAA was performed by
means of immunonephelometry with the Behring
Nephelometer Analyzer II (BNII). For CRP and SAA
measurements, the N High Sensitivity and the N Latex
SAA kits (Dade Behring Gmbh, Germany) were used,
respectively. The control and standard sera were pro-
vided by the same company, and used according to the
manufacturer’s instructions.
Statistical Analysis
Variables were first tested for normality. Normal vari-
ables are expressed as mean ± SD (standard deviation)
while variables with skewed distribution are expressed as
median (interquantile range). If the normality assump-
tion was satisfied for the comparison of means between
two groups, Student’s t-tests were used and Mann-
Whitney tests otherwise. For multiple group compari-
sons the Kruskal-Wallis test was applied. Qualitative
variables are expressed as absolute and relative frequen-
cies. S100A12 was tested for its ability to predict UC
and CD using receiver operating characteristic (ROC)
curves. The overall performance of the ROC analysis
was quantified by computing area under the curve
(AUC). An area of 1 indicated perfect performance,
while 0.5 indicated a performance that was not different
than chance. Using ROC analysis the cut-off values,
with the optimal sensitivity and specificity, for the pre-
diction of UC and CD, were also calculated. Spearman
correlation coefficients were used to explore the associa-
tion of S100A12 with SAA and CRP values, CDAI and
CAI, as well as disease duration. P-values for S100A12
with respect to the severity of disease were also com-
puted. For the comparison of proportions, chi-square
tests were used. All P values are two-tailed. Statistical
significance was set at P < 0.05 and analyses were con-
ducted using STATA statistical software (version 6.0).
Ethical Considerations
Informed consent was obtained from all patients included
in the present study, along with a verbal permission for
the use of the samples acquired for scientific research. The
study was approved by the ethical committee of the School
of Medicine of the University of Thessaly, in Larissa,
Greece.
Results
S100A12 levels with regard to disease characteristics
The median value of serum S100A12 levels was 68.2 ng/mL
(range: 43.4-147.4) for UC patients and 70 ng/mL for CD
patients (range: 41.4-169.8). IBS patients, on the other
hand, exhibited a median of 43.4 ng/mL (range: 34.4-74.4)
while no statistically significant differences were observed
between D-IBS (median: 45.2 ng/mL, range: 34-85.1)
and M-IBS (median: 44.1 ng/mL, range: 36.7-87.5) patients
(P = 0.89). The recorded difference in S100A12 median
values between UC and IBS was significant (P = 0.001) and
this was also the case when CD and IBS median values
were compared (P = 0.001).
ROC curve analysis showed that the optimal cut-off of
S100A12 for the prediction of UC was 54.4 ng/ml, with
a 68.8% sensitivity and a 64.4% specificity. Similarly, the
S100A12 serum value of 55 ng/mL represented the opti-
mal cut-off for the prediction of CD, with a sensitivity
o f6 4 . 1 %a n das p e c i f i c i t yo f6 4 . 4 % .T h ea r e au n d e rt h e
curves (AUCs) was 0.67 (95% CI: 0.58-0.76) and 0.67
(95% CI: 0.58-0.76), for thep r e d i c t i o no fU Ca n dC D ,
respectively, and statistically significant (P =0 . 0 0 1 ,i n
both cases). Furthermore, ROC analysis (Figure 1)
demonstrated that when a cut-off for S100A12 serum
levels of 54.4 ng/mL was used, both UC and CD could
be predicted with a 66.7% sensitivity and 64.4% specifi-
city. The AUC, in this case was 0.67 (95% CI: 0.60-0.75)
(P < 0.001).
Serum S100A12 levels were also studied while consid-
ering disease activity. S100A12 serum levels of IBD
patients with active and inactive disease were both higher
than those of IBS individuals (P = 0.02 in both cases).
Although patients with active disease seemed to exhibit
an increased median of 70.5 (42.6-142.2 ng/mL) com-
pared to that of patients with inactive IBD, which was
64.5 (43.1-192.3 ng/mL), this difference did not prove
significant (P = 0.546). Likewise, when the association of
serum S100A12 with CDAI and CAI was examined no
significant correlations emerged (Spearman r: 0.08 and
0.07, respectively and P ≈ 0.4, in both cases).
A similar observation was made when S100A12 levels
were compared among CD patients with diverse disease
Figure 1 ROC curve for the prediction of both ulcerative colitis
and Crohn’s disease from serum S100A12.
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non-penetrating (ns/np). The performed analysis showed
no associations between S100A12 and CD behavior, since
patients with stricturing (median: 62.1 ng/mL, range:
32-141.2 ng/mL), penetrating (median: 73.5 ng/mL,
range: 41.2-136.7 ng/mL) or ns/np (median: 78.4 ng/mL,
range: 29.3-157.6 ng/mL) disease had comparable levels
(P = 0.321).
The variations in the median of serum S100A12 did
not show a significant association with either disease
extent, in UC (P = 0.590) or disease location in CD (P =
0.512) (Table 2). Similar results were obtained when dis-
ease duration was taken into account. S100A12 serum
concentration was not associated with disease duration
since a low Spearman correlation coefficient (r: 0.09)
and level of significance (P = 0.532) were recorded.
Serum S100A12 levels were also examined with respect
to the presence of one or more IBD-related extraintest-
inal manifestations. No significant differences regarding
S100A12 values were found betwen IBD subjects with
(median: 63.9 ng/mL, range: 38.6-153.7 ng/mL) or with-
out (median: 78.5 ng/mL, range: 51.6-156.9 ng/mL)
extraintestinal manifestations (P = 0.293).
S100A12 levels with focus on patients’ characteristics
S100A12 did not fluctuate significantly when male
(median: 69.5 ng/mL, range: 43.1-167.3 ng/mL) and
female (median: 70.5 ng/mL, range: 42.6-123.8 ng/mL)
IBD patients were compared (P = 0.729). Similarly, no
statistically significant differences or trends were
recorded when serum S100A12 levels were studied
under the light of age at onset (P > 0.1).
Considering the smoking habits of subjects in the IBD
group, although at first glance, higher S100A12 serum
levels in UC non-smokers (median: 72.4 ng/mL, range:
47.6-152.6 ng/mL) compared to UC current smokers
were observed, this difference did not reach statistical
significance (P = 0.215). Similarly, although higher
S100A12 serum levels in CD patients were related to a
current smoking status (median: 78.0 ng/mL, range:
40.1-156.9 ng/mL), the difference between CD current
smokers and CD non-smokers was also non-significant
(P = 0.592) (Table 3).
Finally, the levels of serum S100A12 did not seem to
have any correlation with treatment modalities (5-ASA,
corticosteroids, immunosuppressants, anti-TNF) (P >
0.05 in all cases) (Table 4). As for the need for surgery,
safe comparison could not be performed since surgical
interventions had been applied in only three cases.
S100A12 with respect to CRP and SAA levels
S100A12 was also examined with respect to the known
inflammatory markers CRP and SAA. Patients with active
IBD had statistically significant higher CRP levels (median:
2.27 mg/dL, range: 0.75-31.15 mg/dL) compared to
patients with inactive disease (median: 1.10 mg/dL, range:
0.00-19.20 mg/dL), (P = 0.002). Similarly, SAA levels were
greater in active (median: 8.66 mg/dL, range: 0.20-84.4
mg/dL) than in inactive IBD (median: 6.25 mg/dL, range:
0.10-58.8 mg/dL), (P = 0.001). A significant positive corre-
lation was found between SAA and S100A12 (r = 0.22,
P = 0.018) as well as between CRP and S100A12 (r = 0.35,
P <0 . 0 0 1 ) .
Discussion and Conclusions
IBD has been long ago recognized as a systemic inflam-
matory entity and as such, it is anticipated to induce
changes exceeding the boundaries of bowel mucosa,
being reflected in a broader spectrum of tissues, includ-
ing blood [16-19]. Examples of such changes are the fluc-
tuations in the levels of CRP, SAA, TNF-a,I n t e r l e u k i n s
[16], S100 proteins [17], metalloproteinases [18], angio-
genins [19] etc. Some of these substances have been
introduced as inflammatory markers and used in clinical
practice for diagnostic purposes in patients with sus-
pected or confirmed IBD. The sufficiency of these mar-
kers, however, has been challenged repeatedly due to a
moderate performance, making the study of new markers
in IBD mandatory [17,20,21]. There are numerous stu-
dies examining the significance of several fecal, serum or
mucosal markers including members of the S100 protein
family such as S100A8/9 and S100A12 [3,4,8,22,23].
Since the vast majority of available literature is focused
on S100A8/9 [22,23] and to a lesser extent on S100A12
[6-10] and their role in IBD, a subsequent gap in the
literature regarding S100A12 studies in IBD patients ori-
ginated. Moreover, two serum S100A12 studies were car-
ried out in children [7,10] while only one was conducted
in an adult population [8].
Over the past years, several markers emerged to facili-
tate the differentiation of IBD from IBS. The most pro-
mising among these were fecal S100A8/A9 [24-26] and
Table 2 Median values of S100A12 according to the
extent of UC or location of CD
S100A12
N Median (range) P*
UC
Proctitis 18 50.4 (33-78.3) 0.590
Left-sided colitis 22 102.1 (54.4-142.3)
Pancolitis 24 62.6 (43.4-141.2)
CD
Ileitis 22 122.8 (47.8-199.5) 0.512
Colitis 11 34.3 (29-40.1)
Ileocolitis 31 70.5 (49.1-289.8)
UC: ulcerative colitis, CD: Crohn’s disease.
*Kruskal-Wallis test.
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discriminate IBD from IBS with a sensitivity of 86% and
specificity of 96% [9]. In our study, a significant eleva-
tion in serum S100A12 levels correlated well with IBD
but not with IBS, thus allowing the distinction between
the two entities. The performed analysis also focused on
the determination of a cut-off for IBD prediction that
would exhibit the highest possible sensitivity and specifi-
city. This optimal cut-off was estimated at 54 ng/mL
and was shown to predict both CD and UC with a sen-
sitivity of 66.7% and a specificity of 64.4%, in the popu-
lation of the study. Although, this performance is
superior to the one reported by Sidler et al (21% sensi-
tivity and 81% specificity) [7] still remains moderate and
evidently, lower than that reported for fecal S100A12
[9], probably due to the fact that fecal stream is in direct
contact with the inflamed mucosa. Perhaps, a better
diagnostic performance could be established while asses-
sing simultaneously S100A12 and other IBD-related
diagnostic markers, in serum, a model already applied
when anti-glycan antibody determinations are carried
out [27].
As shown in the results section, a significant correla-
tion between S100A12 serum levels and disease activity
or factors (ie treatment) that can alter the activity could
not be established. Both UC and CD patients with active
disease seemed to have higher values of S100A12 in
serum, compared to IBD subjects with inactive disease
but this difference was not statistically significant. On the
other hand, this “flaw”, could also be regarded as a bene-
ficial characteristic, as it implies that the value of serum
S100A12 for discrimination of IBD from IBS cannot be
challenged by the presence of inactive disease. Although
our findings could be the result of the rather small num-
ber of patients recruited in the study, they are in accor-
dance with previous reports on the inadequacy of serum
S100A12 as a marker for monitoring IBD activity [9],
although in an earlier study, S100A12 concentration in
serum has been shown to differentiate active from inac-
tive IBD [8]. In that study, however, the levels of serum
S100A12 in UC patients with inactive disease were com-
parable to those in healthy controls [8].
According to our results, serum S100A12 determina-
tion could not be used to predict disease extent in UC
patients, since the S100A12 serum values were not signif-
icantly different in patients with proctitis, left-sided colitis
or pancolitis. Similarly, by relying on S100A12 serum
levels, disease location could not be predicted, despite the
fact that, at first glance, patients with ileocolitis or ileitis
seemed to exhibit higher values of serum S100A12, com-
pared to those with CD colitis alone. The data presented
by Foell et al, on the other hand, were indicative of a pre-
dominant mucosal release of S100A12, from the inflamed
colon of CD patients. In the same study, S100A12-stained
neutrophils which adhered to the endothelium of blood
vessels were detected in the CD-affected terminal ileum
[28]. Although no hard evidence favoring this assumption
are available, it would be useful to examine the possibility
that the S100A12 in serum of CD patients may derive
mainly from neutrophils migrating through the blood
vessels into the diseased ileum or that ileal inflammation
triggers a more “systemic” type of response.
Table 3 Median values of S100A12 according to smoking status
S100A12
IBD UC CD
N Median
(range)
P* N Median
(range)
P* N Median
(range)
P*
Smoking No 75 64.5
(44.2-154)
0.813 54 72.4
(47.6-152.6)
0.215 21 56
(42.6-199.5)
0.592
Yes 53 78.0
(39.1-142.2)
10 54.6
(28.1-133.2)
43 78
(40.1-156.9)
UC: ulcerative colitis, CD: Crohn’s disease.
*Mann-Whitney test.
Table 4 Median values of S100A12 according to clinical
characteristics and treatment
S100A12
N Median
(Interquartile
range)
P*
Activity Active 40 70.5 (42.6-142.2) 0.546
Inactive 88 64.5 (43.1-192.3)
Extraintestinal
manifestations
None 77 63.9 (38.6-153.7) 0.293
≥1 51 78.5 (51.6-156.9)
5-ASA No 25 61.2 (34.3-133.2) 0.210
Yes 103 74.4 (44.2-157)
Corticosteroids No 57 63.9 (37.3-136.4) 0.285
Yes 71 74.4 (47.6-157)
Immunosuppressants No 93 64.5 (43.1-142.2) 0.340
Yes 35 83.5 (42.9-282.0)
Anti-TNF No 109 69.5 (43.6-152.6) 0.896
Yes 19 70.5 (38.6-157.0)
*Mann-Whitney or Kruskal-Wallis tests.
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to the presence of any extraintestinal manifestations, no
significant variations became evident. S100A12 serum
concentrations were comparable between IBD patients
with or without extraintestinal manifestations.
The effect of current smoking status on serum
S100A12 concentration, in IBD individuals was also
examined, since smoking has been traditionally regarded
as a factor which could improve UC and worsen CD [29].
As shown above, the levels of S100A12 in serum of
current smokers, diagnosed with CD appeared to be
elevated, compared to CD non-smokers. In the UC
group, the levels of serum S100A12 seemed to be higher
in non-smokers than in those found in current smokers.
These findings, although within reason, lack credibility
since, neither statistical significance nor trend could be
reached for any of the recorded smoking-related
associations.
Similarly, all treatment modalities, leading to a subse-
quent disease remission, did not seem to have a notice-
able effect on serum levels of S100A12 in the IBD
group. This result is partly in accordance with an earlier
study in which corticosteroids did not alter significantly
S100A12 serum levels of IBD adults [8]. The impact in
S100A12 serum levels of infliximab-treated IBD subjects
recorded in that study [8] was not verified in ours.
What appears to be of interest is that a statistically
significant association was found between serum
S100A12 levels and the well-known markers of inflam-
mation, CRP and SAA, in the absence of a similar asso-
ciation with IBD activity-determined by conventional
inflammatory indices. Before discarding serum S100A12
as a potential marker for the monitoring of IBD activity
it would, perhaps be better if possible associations with
other indices [30,31] were also evaluated.
At this point a potential study limitation has to be
underlined. The serum S100A12 levels determined in our
population, using the prototypic ELISA described above,
were lower compared to IBD-oriented studies, using
different ELISA assays [7,8,10]. According to the manu-
facturer (CIS bio international, France) this is probably
the result of discrepancies, originating from between-
studies differences in the pre-analytical phase, as well as
the inability of the specific kit to perform equally well
when different blood-containing mediums were used. In
line with this notion are the results from a study on the
impact of diverse sample handling conditions -incubation
in tubes with gel/anticoagulants/calcium, dilution with
calcium containing buffers, different storing conditions,
repeated freeze-thaw cycles etc- revealing great fluctua-
tions in the S100A12 levels, even in blood samples
obtained from healthy individuals [32]. According to
the authors, however, the most reliable blood sample
for S100A12 determinations would be serum stored in
gel-containing tubes, as in our study [32]. The use of the
most suitable -or least unsuitable- type of blood-derived
sample, along with the establishment of identical for all
samples “handling” throughout the critical phase that
preceded analysis, minimise the odds that the between-
subjects differences recorded in our study are due to the
use of the specific ELISA.
In conclusion, it is evident that the upregulation of
S100A12 is not confined to the boundaries of an IBD-
occupied intestine but is also reflected systemically and
subsequently detected in serum. This increase in serum
S100A12 is associated with IBD and is also well corre-
lated with the “classic” markers of inflammation CRP and
SAA. On the other hand, since the diagnostic utility of
serum S100A12 was moderate, when used alone, its use
in a “palette” of established serological markers, might
actually lead to an improved overall diagnostic perfor-
mance. Thus, it seems that further research in larger
populations is mandatory, in order to verify these results,
examine the association of serum S100A12 with disease
or patients’ characteristics and specify whether serum
S100A12 could be added in the existing armamentarium,
used for the diagnosis of IBD.
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